This is the type of information that I appreciate. Over the last few weeks the public focus of the company has shifted from validating LYMPRO to the marketing of LYMPRO. Sure, they are busy with other assets but they are highlighting the revenue that is coming with LYMPRO.
So what if the initial sales are disappointing to some. They are initial to be followed by subsequent. If for no other reason than the statements identified by RedSpeed were provided by todays conference then I would say it was a tremendous success.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links